IntrinsicIntrinsic
← All summaries

AtaiBeckley Inc.

ATAI
Financials & Chart →

Business Summary

AtaiBeckley Inc. is a clinical-stage biotechnology company formed in 2025 through the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited, focused on developing treatments for difficult-to-treat mental health conditions . The company operates within an industry where mental health disorders affect over one billion people globally, with U.S. mental healthcare spending reaching $225.0 billion in 2019 and global economic costs projected to hit $16.0 trillion by 2030 . A significant unmet medical need exists, as approximately 65% of patients do not achieve remission after up to four antidepressant treatment trials .

The company's core business model revolves around the rigorous scientific development of a diversified pipeline of investigational psychedelic-based neuroplastogens and novel non-hallucinogenic compounds. Revenue generation is currently focused on research and development services, with future profitability dependent on successful commercialization of approved products. The primary customer segments are patients suffering from mental health disorders such as treatment-resistant depression (TRD) and social anxiety disorder (SAD).

AtaiBeckley's pipeline includes several key product candidates. BPL-003 is a nasal spray mebufotenin (5-MeO-DMT) benzoate being developed for treatment-resistant depression (TRD) . VLS-01 is a buccal film dimethyltryptamine (DMT) also targeting TRD . EMP-01 is an oral formulation of R-MDMA for social anxiety disorder (SAD) . Additionally, the company has a drug discovery program focused on identifying novel, non-hallucinogenic 5-HT2AR agonists for TRD and Opioid Use Disorder (OUD) .

For the fiscal year ended December 31, 2025, AtaiBeckley reported a net loss attributable to AtaiBeckley, Inc. stockholders of $660.0 million . As of December 31, 2025, the company held cash and cash equivalents of $85.3 million and short-term securities of $135.4 million . The company's intellectual property portfolio includes over 100 issued patents and over 200 pending applications worldwide, with 41 issued U.S. patents, 54 pending U.S. patent applications, 13 pending U.S. provisional applications, and 21 PCT applications .

Year-over-year, the net loss attributable to AtaiBeckley, Inc. stockholders significantly increased from $149.3 million in 2024 to $660.0 million in 2025 . This reflects increased investment in research and development and operational expenses.

Significant operational developments during the period include the strategic combination of atai Life Sciences N.V. and Beckley Psytech Limited in November 2025, leading to the company's name change to Atai Beckley N.V. . On December 30, 2025, the company completed a Redomiciliation Transaction, changing its corporate domicile from the Netherlands to the United States and becoming AtaiBeckley Inc. . In October 2025, BPL-003 received breakthrough therapy designation for the treatment of adult patients with treatment-resistant depression . The company also announced positive topline results from the Phase 2b study of BPL-003 in July 2025, meeting its primary and all key secondary endpoints, with the 8 mg dose selected for advancement into Phase 3 clinical studies . In November 2025, positive top-line results from the Phase 2b open-label extension (OLE) study of BPL-003 were announced, supporting the potential for additional benefit with repeat dosing . In February 2026, positive topline results from the exploratory Phase 2a study of EMP-01 in adults with SAD were announced, meeting its primary endpoint of safety and tolerability and demonstrating clinically meaningful improvements . In August 2025, the company was awarded a multi-year, milestone-driven grant of up to $11.4 million from the National Institute on Drug Abuse (NIDA) to support the optimization and early-stage development of its novel 5-HT2A/2C receptor agonists for opioid use disorder . The company also conducted a reduction in force of approximately 10% in February 2024 and 25% in March 2025 of its global workforce .

Business Outlook

AtaiBeckley estimates that its existing cash, including proceeds from its public offering of common stock, marketable securities, and committed term loan funding as of the date of this Annual Report on Form 10-K, will be sufficient to fund operations into 2029 .

A major growth area for the company is the advancement of BPL-003 for Treatment-Resistant Depression (TRD). Following an End-of-Phase 2 meeting with the FDA in February 2026, the company obtained feedback on the design of the Phase 3 clinical program, which will consist of two pivotal trials, ReConnection 1 and ReConnection 2 . ReConnection 1 will enroll approximately 350 participants and evaluate a single-dose of BPL-003 across three treatment arms (8 mg, 4 mg, and placebo), aiming to replicate and extend Phase 2b results and characterize the dose-response relationship . ReConnection 2 will enroll approximately 300 participants and evaluate a two-dose induction model of BPL-003 (8 mg on Day 1 and Day 15) against placebo, designed to investigate increased magnitude and durability of initial response . The primary endpoint for both trials will be the change from baseline in the MADRS total score at Week 4 (Day 29) for the 8 mg BPL-003 arm compared to placebo . The open-label extension (OLE) in both studies will allow individualized retreatment with 8 mg BPL-003 at 8- or 12-week intervals, subject to eligibility criteria, to assess long-term safety, durability, and treatment patterns . Initiation of the Phase 3 program is planned for the second quarter of 2026 .

Another significant growth area is the development of VLS-01 for TRD. The company initiated the Elumina Phase 2 randomized, double-blind, placebo-controlled trial in March 2025, evaluating VLS-01 in adults with TRD . This study includes two treatment periods, with the first period randomizing approximately 142 patients to receive a 120mg dose of VLS-01 or placebo on Day 1 and Week 2 . The primary endpoint is change from baseline in MADRS total score at Week 4, with follow-up to Week 14 . The second treatment period will explore responses to two different dose levels (60mg or 120mg) of VLS-01 as a third dose at Week 14 . Topline results from the Elumina study are anticipated in the second half of 2026 .

The company's operational outlook includes a focus on managing its workforce. In February 2024 and March 2025, the company conducted reductions in force of approximately 10% and 25%, respectively, of its global workforce to align with its current business model . This indicates a strategy to optimize cost structure and efficiency.

In terms of planned capital allocation, the company received aggregate net proceeds of $51.9 million from an underwritten public offering of 26,190,477 common stock in February 2025, and an additional $7.8 million from the underwriter's exercise of its option to purchase 3,928,571 common stock . In October 2025, the company issued and sold 23,725,000 common shares in an underwritten offering, receiving aggregate net proceeds of approximately $121.7 million, and an additional $18.2 million from the underwriter's exercise of its option to purchase 3,558,750 common shares . The company also has an Open Market Sale Agreement with Jefferies LLC, allowing it to issue and sell common stock with an aggregate offering price of up to $150.0 million through an "at the market" equity offering program .

Risk Factors

AtaiBeckley faces numerous material risks, including significant losses since inception and the expectation of continued losses for the foreseeable future, with no guarantee of profitability . The company's limited operating history makes it difficult to evaluate future viability, and a failure to obtain additional funding on acceptable terms could force delays or discontinuation of product candidate development efforts . The success of product candidates is uncertain, as they are in preclinical or clinical development, which is lengthy, expensive, and prone to failure at any stage . Research and development of central nervous system (CNS) drugs is particularly difficult, with high failure rates and challenges in predicting drug effects . The production and sale of product candidates containing controlled substances may be considered illegal or restricted in certain jurisdictions, potentially affecting commercialization and the legality of foreign investments . The company faces significant competition from major pharmaceutical and biotechnology companies with greater resources, and competitors may achieve regulatory approval sooner or develop superior therapies . Reliance on third parties for clinical trials and preclinical testing poses risks of unsatisfactory performance or missed deadlines . Inadequate intellectual property protection could allow competitors to commercialize similar products, impairing AtaiBeckley's ability to commercialize its own candidates . Third parties may claim infringement of their intellectual property rights, leading to uncertain and costly litigation . The business is also exposed to global financial and economic conditions, geopolitical events, and international operational risks, including compliance with anti-corruption and trade control laws . Cyberattacks, data security incidents, or failures in IT systems could lead to information theft, legal liability, and business disruption . Disruptions at regulatory agencies due to funding shortages or government shutdowns could delay product development or capital raising . The company's use of existing cash to purchase highly volatile digital currencies like bitcoin exposes it to significant price fluctuations and regulatory uncertainties .

Management Priorities

Management's overall tone emphasizes a mission to create breakthroughs for people with difficult-to-treat mental health conditions, grounded in rigorous science to deliver meaningful outcomes. They highlight a commitment to leading a new era of mental health treatment focused on improved quality of life and lasting change. Key strategic priorities include advancing the diversified pipeline of investigational psychedelic-based neuroplastogens and novel non-hallucinogenic compounds, with a particular focus on BPL-003, VLS-01, and EMP-01. Management has communicated specific guidance regarding the sufficiency of existing cash, marketable securities, and committed term loan funding to fund operations into 2029 . They also explicitly stated the plan to initiate the Phase 3 program for BPL-003 in the second quarter of 2026 and anticipate reporting topline data for the Elumina study of VLS-01 in the second half of 2026 . The company also emphasizes its commitment to innovation, intellectual property development, and embedding lived experience at the center of its work through patient impact initiatives.

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 1, Business
  2. [2] Item 1, Business
  3. [3] Item 1, Business
  4. [4] Item 1, Business — Our Programs
  5. [5] Item 1, Business — Our Programs
  6. [6] Item 1, Business — Our Programs
  7. [7] Item 1, Business — Our Programs
  8. [8] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  9. [9] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  10. [10] Item 1, Business — Overview of our Intellectual Property
  11. [11] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  12. [12] Item 1, Business
  13. [13] Item 1, Business — Redomiciliation
  14. [14] Item 1A, Risk Factors — Risks Related to the Clinical Development, Regulatory Review and Approval of our Product Candidates.
  15. [15] Item 1, Business — BPL-003: Mebufotenin benzoate for TRD
  16. [16] Item 1, Business — BPL-003: Mebufotenin benzoate for TRD
  17. [17] Item 1, Business — EMP-01: R-MDMA for SAD
  18. [18] Item 1, Business — Novel 5-HT2A Receptor Agonists (including non-hallucinogenic neuroplastogens)
  19. [19] Item 1A, Risk Factors — Risks Related to Our Business and Industry
  20. [20] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  21. [21] Item 1, Business — BPL-003: Mebufotenin benzoate for TRD
  22. [22] Item 1, Business — BPL-003: Mebufotenin benzoate for TRD
  23. [23] Item 1, Business — BPL-003: Mebufotenin benzoate for TRD
  24. [24] Item 1, Business — BPL-003: Mebufotenin benzoate for TRD
  25. [25] Item 1, Business — BPL-003: Mebufotenin benzoate for TRD
  26. [26] Item 1, Business — BPL-003: Mebufotenin benzoate for TRD
  27. [27] Item 1, Business — VLS-01: DMT for TRD
  28. [28] Item 1, Business — VLS-01: DMT for TRD
  29. [29] Item 1, Business — VLS-01: DMT for TRD
  30. [30] Item 1, Business — VLS-01: DMT for TRD
  31. [31] Item 1, Business — VLS-01: DMT for TRD
  32. [32] Item 1A, Risk Factors — Risks Related to Our Business and Industry
  33. [33] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  34. [34] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  35. [35] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  36. [36] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  37. [37] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  38. [38] Item 1A, Risk Factors — Risks Related to the Clinical Development, Regulatory Review and Approval of our Product Candidates.
  39. [39] Item 1A, Risk Factors — Risks Related to the Clinical Development, Regulatory Review and Approval of our Product Candidates.
  40. [40] Item 1A, Risk Factors — Risks Related to Commercialization
  41. [41] Item 1A, Risk Factors — Risks Related to Commercialization
  42. [42] Item 1A, Risk Factors — Risks Related to Reliance on Third Parties
  43. [43] Item 1A, Risk Factors — Risks Related to Our Intellectual Property
  44. [44] Item 1A, Risk Factors — Risks Related to Our Intellectual Property
  45. [45] Item 1A, Risk Factors — Risks Related to Our International Operations
  46. [46] Item 1A, Risk Factors — Risks Related to Our Business and Industry
  47. [47] Item 1A, Risk Factors — Risks Related to Our Business and Industry
  48. [48] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  49. [49] Item 1A, Risk Factors — Risks Related to our Financial Position, Need for Additional Capital and Growth Strategy
  50. [50] Item 1, Business — BPL-003: Mebufotenin benzoate for TRD
  51. [51] Item 1, Business — VLS-01: DMT for TRD

Analysis on 5/22/2026